Archive
This is a library of Lhasa's blog articles.
Filter by Category
Filter by Author
- Alex Cayley
- Alex Harding
- Ally Reeves
- Alun Myden
- Anax Oliveira
- Andrew Thresher
- Ash Ali
- Cheuk Man Tsang
- Chris Barber
- Crina Heghes
- Daragh Connolly
- Dave Yeo
- David Ponting
- Emma Scrafton
- Fabrizio Campo
- Fernanda Waechter
- Grace Kocks
- Hazel Gardiner
- James McManus
- Jess Tidmarsh
- Jessica Magallanes-Castaneda
- Josh Cosby
- Kelly Gallagher
- Laura Johnston
- Liz Covey-Crump
- Martyn Chilton
- Michael Burns
- Nik Marchetti
- Oana Leonte
- Paul Imeson
- Pearl Saville
- Rachael Tennant
- Rachel Hemingway
- Raeesah Saddiq
- Rob Foster
- Sara Atkinson
- Scott McDonald
- Susanne Stalford
Filter by Product
How to calculate the safe limit for carcinogens as per ICH M7
Mutagenic impurities can be expected in any drug product; however, this is not a concern providing they are present below the safe limit. The objective of a carcinogenicity study is to identify compounds that can cause tumours in animals, which is imperative to understanding the cancer risk posed to humans.
07 November 2022
Supporting N-nitrosamine risk assessments for drug products
N-Nitrosamine risk assessment and control have become an integral part of pharmaceutical drug product development. In this article, we discuss 3 key stages of risk assessment: identifying the source of risk, determining the level of activity and mitigating the risk. Discover how our in silico tools can be used to support informed decision making on chemical safety, in this blog article.
25 July 2022
5 things you should know about the data in the Lhasa Carcinogenicity Database (LCDB)
Would your toxicology assessments benefit from free access to long-term carcinogenicity study data? The Lhasa Carcinogenicity Database (LCDB) is a widely used, free resource of long-term carcinogenicity study data.
In this article we explore 5 things you should know about the data in the LCDB.
25 May 2022
Accessing vital sources of long-term carcinogenicity study data with Lhasa’s Carcinogenicity Database
In this blog piece, we explore in more detail, the features of the recent release and how they will benefit LCDB users.
12 July 2021
Comparing CPDB and Lhasa TD50 values in the Lhasa Carcinogenicity Database
For many years the Carcinogenic Potency Database (CPDB)1, created by Lois Gold and her team, was an important source of long-term carcinogenicity study data. However, as the database had stopped being updated from 2007, Lhasa moved to safeguard the data by providing ongoing access through a freely available interface; the Lhasa Carcinogenicity Database (LCDB)2. The LCDB was released in 2016 and has since been updated with additional data from the National Toxicology Program (NTP)3, increasing the data set to 7,745 studies covering 1,726 chemical substances. A recent update has also facilitated greater ease of access by enabling substructure and similarity-based structure queries.
08 December 2020
Lhasa Limited supports the global challenge of nitrosamine impurity assessment
The recent discovery of N-nitrosamine (nitrosamine) impurities in several marketed pharmaceuticals has led to a requirement for further investigation into nitrosamine mutagenic and carcinogenic activity. Regulatory requirements mean that marketing authorisation holders for human medicines, containing chemically synthesised active substances, must review their medicines for the possible presence of nitrosamines and test all products at risk. Risk-based approaches to prioritise evaluations and subsequent confirmatory testing may be used. These assessments must be completed by October 2020, generating a significant challenge for the pharmaceutical industry.
13 July 2020